NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. The gene discussed is KLRC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.